CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025

CONMED Corp

Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.
He serves on Corporate Governance & Nominating and Strategy Committees.
Kelderman is President & CEO of Bio-Techne (TECH) since February 2024.
Granted prorated equity valued at ~$134,766 (500 RSUs + options for 6,227 shares).
Prior roles include Thermo Fisher Scientific and Becton Dickinson.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.